Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vaċċini - infanrix penta huwa indikat għall-vaċċinazzjoni primarja u booster tat-trabi kontra diphtheria, tetanus, pertussis, epatite b u poliomyelitis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaċċini - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaċċini - profilassi tal-influwenza kkawżata mill-virus a (h1n1) v 2009. celvapan ma għandu jintuża skont il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - virus tal-herpes tad-dundjan rikombinanti ħajjin assoċjat miegħu (rhvt / nd) li jesprimi l-proteina tal-fużjoni tal-vajrus tal-marda newcastle d-26 razza lenogenika - immunoloġiċi għall-aves, vaċċini virali Ħajjin - chicken; embryonated eggs - għall-immunizzazzjoni attiva ta ' 18-il ġurnata embryonated-bajd tat-tiġieġ jew flieles biex titnaqqas il-mortalità u sinjali kliniċi ikkawżati mill-virus tal-marda newcastle u biex tnaqqas l-imwiet, sinjali kliniċi u leżjonijiet ikkawżati minn marek tal-virus tal-marda bil-fenotip "virulenti".

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol phosphate mill-haemophilus influenzae tat-tip b bħala prp-ompc, il-membrana ta 'barra kumpless tal-proteina tal neisseria meningitidis (il-membrana ta' barra kumpless tal-proteina tar-razza b11 ta 'neisseria meningitidis sottogrupp b), adsorbit ta' l-epatite b-antiġen tal-wiċċ prodott f'ċelloli tal-ħmira rikombinanti (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vaċċini - procomvax huwa indikat għall-vaċċinazzjoni kontra l-marda invażivi ikkawżat minn influwenza Ħemofillika tip b u kontra l-infezzjoni kkawżat mill-sottotipi magħrufa kollha tal-virus tal-hepatitis b fit-trabi 6 ġimgħat sa 15-il xahar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios hipra, s.a. - virus ħaj inattivat tal-marda burżali infettiva tal-virus (ibdv), razza 1052 - immunoloġiċi għall-aves, tjur domestiċi, vaċċini virali Ħajjin, tat-tjur tal-marda infettiva bursal virus (marda gumboro) - chicken; embryonated chicken eggs - għall-immunizzazzjoni attiva ta ' 1-ġurnata brojlers u embryonated brojlers-bajd tat-tiġieġ sabiex jitnaqqsu s-sinjali kliniċi u leżjonijiet tal-bursa tal-fabricius kkawżata minn ħafna virulenti tat-tjur tal-marda infettiva bursal-infezzjoni tal-virus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - tumur stromali gastrointestinali - aġenti antineoplastiċi oħra, inibituri tal-proteina kinase - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meninġite, meningokokkali - vaċċini - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - rotavirus serotip g1, serotip g2, serotip g3, serotip g4, serotip p1 - immunization; rotavirus infections - vaccines, viral vaccines - rotateq huwa indikat għall-immunizzazzjoni attiva tat-trabi mill-età ta 'sitt ġimgħat sa 32 ġimgħa għall-prevenzjoni ta' gastroenterite minħabba infezzjoni ta 'rotavirus. rotateq għandu jintuża fuq il-bażi ta ' rakkomandazzjonijiet uffiċjali.